Purpose: Gene therapy could induce immunosuppression with greater durability and less toxicity than conventional agents like cyclosporine A, but T cells are notoriously refractory to non-viral gene delivery. An effective, T-cell-targeted, MRI-trackable non-viral vector is needed for immunosuppression in transplantation and autoimmune disease.
Hypothesis: If a CD3 single-chain antibody (scAbCD3) and superparamagnetic iron oxide nanoparticles (SPIONs) are conjugated to poly(ethylene glycol)-grafted polyethyleneimine (PEG-g-PEI), then the resulting polyplex will specifically target T cells via CD3 receptor-mediated endocytosis, enhance gene transfection (including the therapeutic DGKα gene), induce T-cell anergy, and be visible by MRI.
Aims: Synthesize scAbCD3-PEG-g-PEI-SPION and formulate polyplexes with plasmid DNA. - Characterize DNA condensation, particle size, zeta potential, and cytotoxicity. - Evaluate CD3-mediated cellular uptake and MRI visibility in HB8521 rat T lymphocytes. - Assess transfection efficiency with reporter (EGFP) and therapeutic (DGKα) genes. - Evaluate T-cell anergy (proliferation and IL-2 expression) after DGKα delivery.
Delivery system:
Component: Polymer; Details: PEG-grafted polyethyleneimine (PEG-g-PEI)
Component: Targeting ligand; Details: CD3 single-chain antibody (scAbCD3) conjugated to distal PEG ends
Component: Imaging agent; Details: Superparamagnetic iron oxide nanoparticles (SPIONs, ~6 nm), incorporated via ligand exchange; ~55 wt% Fe
Component: Payload; Details: pAAV-EGFP (reporter); pcDNA3.1-DGKα-flag (therapeutic)
Component: Polyplex formulation; Details: N/P 10 for transfection and uptake studies; N/P 1.7–2.5 for gel retardation; N/P 3–10 for western blot
Component: Target cells; Details: HB8521 rat T lymphocyte line
Component: Key feature; Details: Dual-purpose: T-cell targeting plus MRI T₂ contrast for non-invasive tracking
Approach: In vitro only. No in vivo animal studies (animal tests mentioned as ongoing). - Cell line: HB8521 rat T lymphocyte line. - Cytotoxicity: WST-8 assay; N/P 5–30; DNA 0.15 µg/well. - Uptake: Confocal laser scanning microscopy (CLSM) with multiple fluorescent labeling; free CD3 antibody competition assay. - MRI: 1.5 T scanner; Fe concentrations 5–80 µg/mL; T₂-weighted images; SNR and r₂ relaxivity. - Transfection: Flow cytometry and fluorescence microscopy; western blot for DGKα. - Anergy: [³H]thymidine proliferation assay; IL-2 ELISA after PMA/ionomycin stimulation. - Statistics: One-way ANOVA; p < 0.05; n = 3 (quadruplicate for anergy assays).
Key methods: Gel retardation assay: DNA condensation at various N/P ratios. - WST-8 assay: Cytotoxicity. - CLSM: Cellular uptake and competitive inhibition. - MRI: T₂-weighted imaging, SNR, relaxivity (r₂). - Flow cytometry: Reporter gene (EGFP) transfection efficiency. - Western blot: DGKα protein expression (anti-DGKα antibody). - ELISA: IL-2 cytokine expression. - [³H]thymidine incorporation: T-cell proliferation.
Key results: DNA condensation: Full retardation at N/P ~2.3 for both PEG-g-PEI and PEG-g-PEI-SPION; SPION did not impair condensation. - Cytotoxicity: PEG-modified polyplexes showed much lower cytotoxicity than PEI 25 kDa. At N/P 10, ~75% viability for PEG-modified vs ~30% for PEI (about 70% cell death). - Uptake: scAbCD3-targeted polyplexes were efficiently internalized; non-targeting polyplexes showed very low uptake. Free CD3 antibody pre-treatment inhibited internalization, confirming CD3 receptor-mediated endocytosis. - MRI: Targeted polyplexes produced significantly greater T₂ signal decrease (SNR reduction) than non-targeting polyplexes at Fe ≥10 µg/mL. - Transfection: Non-targeting: 5.60 ± 1.45% (PEG-g-PEI) and 7.39 ± 2.21% (PEG-g-PEI-SPION). Targeting: 75.78 ± 5.5% and 81.95 ± 5.73% — about 16-fold enhancement. Half-ligand density reduced efficiency to 30.33 ± 2.86% and 39.35 ± 8.65%. - Therapeutic gene: DGKα expression was significantly higher with targeting polyplexes at all N/P ratios (3, 5, 10), highest at N/P 10. - Anergy: DGKα-transfected cells showed reduced proliferation (CPM ~6,700 vs ~11,800 for PMA+IO) and reduced IL-2 production (~42 pg/mL vs ~72 pg/mL for PMA+IO) — about 43% inhibition of proliferation and 38% inhibition of IL-2 expression.
Interpretation: The authors claim that scAbCD3-PEG-g-PEI-SPION is an effective T-cell-targeted, MRI-visible non-viral gene delivery platform. CD3 receptor-mediated endocytosis dramatically enhances transfection in T lymphocytes, and delivery of DGKα induces T-cell anergy in vitro. The system may enable non-invasive MRI tracking of targeted gene delivery for post-transplantation immunotherapy and autoimmune disease treatment.
Limitations: In vitro only: No in vivo data; animal tests are mentioned as ongoing but not reported. - Single cell line: HB8521 rat T lymphocyte line; primary T cells only mentioned as "initial results promising" without data. - No targeting specificity data in mixed cell populations or in vivo biodistribution. - No long-term expression or safety data. - MRI validation limited to cell pellets in vitro — no in vivo imaging. - No comparison with viral vectors. - DGKα anergy mechanism inferred from downstream proliferation/IL-2 data, not directly measured TCR signaling. - No dose–response optimization for the therapeutic gene or SPION content. - SPION leaching or stability in biological media not systematically assessed.
